Only a few studies have investigated changes in the dose of long-acting injectable second-generation antipsychotics (LAI-SGAs) over the long term in the maintenance treatment of schizophrenia. In this retrospective cohort study, we examined longitudinal changes in antipsychotic dose over a 3-year period in patients with schizophrenia who had been taking LAI-SGAs for at least 1 year. We compared the total daily chlorpromazine equivalent dose of antipsychotics at 12, 24 and 36 months with the baseline dose at 3 months after initiation of LAI-SGAs. We also performed multiple regression analysis to explore factors associated with change in total daily dose 12 months after treatment initiation. A total of 154 patients fulfilled the inclusion criteria. There was no significant difference in total daily antipsychotic dose between 3 months and 12, 24 or 36 months after treatment initiation. Total daily dose was increased in 43 (27.9%), 31 (34.8%) and 22 patients (36.7%) at 12, 24 and 36 months, respectively. Age and total antipsychotic dose at 3 months were significantly negatively associated with change in total daily dose. Antipsychotic dose was basically unchanged during long-term treatment in patients treated with LAI-SGAs in the maintenance phase, although there was an increase in some patients.

中文翻译：

---

接受长效注射第二代抗精神病药治疗的患者抗精神病药剂量的纵向变化。

只有少数研究调查了长期用于精神分裂症维持治疗的长效注射用第二代抗精神病药 (LAI-SGA) 的剂量变化。在这项回顾性队列研究中，我们检查了服用 LAI-SGA 至少 1 年的精神分裂症患者在 3 年内抗精神病药剂量的纵向变化。我们比较了 LAI-SGA 开始后 12、24 和 36 个月时抗精神病药的每日氯丙嗪等效总剂量与基线剂量。我们还进行了多元回归分析，以探讨与治疗开始 12 个月后每日总剂量变化相关的因素。共有154名患者符合纳入标准。在 3 个月和 12 个月之间，抗精神病药的每日总剂量没有显着差异，治疗开始后 24 或 36 个月。在 12、24 和 36 个月时，分别有 43 (27.9%)、31 (34.8%) 和 22 (36.7%) 名患者的每日总剂量增加。3 个月时的年龄和抗精神病药总剂量与每日总剂量的变化显着负相关。在维持期接受 LAI-SGA 治疗的患者在长期治疗期间抗精神病药物剂量基本没有变化，尽管在一些患者中有所增加。